Patents Examined by S. J. Friedman
  • Patent number: 5278172
    Abstract: A process is provided which is useful in alleviating inflammation of tendons and/or joints in a patient in need of such treatment. The process comprises administering a vasodilator to the inflamed tissue, either topically or by injection. Advantageously, the vasodilator is papaverine or a pharmaceutically acceptable salt thereof such as papaverine hydrochloride. Advantageously, the papaverine hydrochloride may be administered topically in a composition comprising a carrier. The carrier dissolves the papaverine hydrochloride and enables it to penetrate the skin and be absorbed into the inflamed tissue.
    Type: Grant
    Filed: July 24, 1992
    Date of Patent: January 11, 1994
    Inventor: Richard K. Hennessey
  • Patent number: 5278160
    Abstract: There are disclosed the use of the compounds of the formula (I) ##STR1## wherein R.sup.1 is 1-adamantyl, 3-methyl-1-adamantyl, 3-noradamantyl, unsubstituted or substituted-2-indolyl, 3-indolyl, 2-benzofuranyl or 3-benzofuranyl wherein the substituents are selected from lower alkyl, lower alkoxy and halo; R.sup.2 is unsubstituted or substituted phenyl, benzyl, or pyrimidinyl wherein the substituents are selected from lower alkyl, lower alkoxy, trifluoromethyl and halo; R.sup.3 is H or lower alkyl of 1 to 3 carbon atoms; n is the integer 0 or 1; and m is the integer from 2 to 5 and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 10, 1992
    Date of Patent: January 11, 1994
    Assignee: American Home Products Corporation
    Inventors: Magid A. Abou-Gharbia, John P. Yardley, Wayne E. Childers, Jr., John A. Moyer
  • Patent number: 5278169
    Abstract: A method for the treatment and prevention of fibrillation using one or more potassium channel activators. Also, disclosed is a process for the preparation of compounds of the formula ##STR1## and the tautomeric forms ##STR2## wherein R''and R" are as defined herein.
    Type: Grant
    Filed: July 9, 1990
    Date of Patent: January 11, 1994
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Karnail Atwal, Gary J. Grover
  • Patent number: 5276031
    Abstract: The present invention relates to the use of renin inhibitors and to renin inhibitor compositions for prevention, treatment, inhibition or reversal of renal dysfunction or disease, especially renal failure.
    Type: Grant
    Filed: October 26, 1992
    Date of Patent: January 4, 1994
    Assignee: Abbott Laboratories
    Inventor: Hollis D. Kleinert
  • Patent number: 5276043
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of certain anabasine compounds, certain unsaturated anabasine compounds or unsaturated nicotine compounds. Exemplary compounds are myosmine and anatabine.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: January 4, 1994
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5276059
    Abstract: The invention provides a method of treating a mammal having a condition associated with formation of amyloidogenic protein without deposition of amyloid plaques. This treatment includes administering to the mammal a pharmacologically effective amount of Congo Red or a pharmaceutically acceptable salt or derivative thereof to interfere with amyloidogenic protein formation or to destabilize amyloidogenic protein structures already formed in said mammal. The invention also provides a method of treating a mammal having a condition associated with deposition of amyloidogenic protein in plaques, and a method of inhibiting the transformation of PrP-sen to PrP-res in a tissue culture sample containing PrP-sen.
    Type: Grant
    Filed: July 10, 1992
    Date of Patent: January 4, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Byron Caughey, Richard Race
  • Patent number: 5276050
    Abstract: The invention relates to the use of compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof, in which Im represents an imidazolyl group of formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenylC.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, --CO.sub.2 R.sup.5, --COR.sup.5, --CONR.sup.5 R.sup.6 or --SO.sub.2 R.sup.5 (wherein R.sup.5 and R.sup.6, which may be the same or different each represents a hydrogen atom, a C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl group, or a phenyl or phenylC.sub.1-4 alkyl group, in which the phenyl group is optionally substituted by one or more C.sub.1-4 alkyl, C.sub.1-4 alkoxy or hydroxy groups or halogen atoms, with the proviso that R.sup.5 does not represent a hydrogen atom when R.sup.1 represents a group --CO.sub.2 R.sup.5 or --SO.sub.2 R.sup.
    Type: Grant
    Filed: July 6, 1992
    Date of Patent: January 4, 1994
    Assignee: Glaxo Group Limited
    Inventors: Steven J. Cooper, Ian H. Coates, Alexander W. Oxford, Peter C. North
  • Patent number: 5273992
    Abstract: The present invention provides a chemical class of active compounds to be used as efficacious drugs in the treatment of sickle cell disease. The active compounds include imidazole derivatives, nitroimidazole derivatives, and triazole derivatives. These compounds are to be administered by any preferred route of administration including oral, intramuscular, intravenous, and any other parenteral route. If desired, these drugs may also be administered transmucosally, or subcutaneously, or using a dermal patch on the skin. In addition, the methodology is effective for both long term and short term therapy; may be employed prophylactically and/or therapeutically; and may be used in emergency, acute crisis clinical situations.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: December 28, 1993
    Assignee: Beth Israel Hospital Assoc. Inc.
    Inventors: Carlo Brugnara, Seth L. Alper
  • Patent number: 5272168
    Abstract: The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.
    Type: Grant
    Filed: January 15, 1993
    Date of Patent: December 21, 1993
    Assignee: Sandoz Ltd.
    Inventors: Assunta Imperato, Dietmar Romer
  • Patent number: 5266594
    Abstract: Inhibitors of nitric acid synthase can be used to prevent neurotoxicity mediated through glutamate receptors. Nitric oxide synthase inhibitors can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimer's disease and Huntington's disease.
    Type: Grant
    Filed: May 12, 1992
    Date of Patent: November 30, 1993
    Inventors: Valina L. Dawson, Ted M. Dawson, Edythe D. London, David S. Bredt, Solomon H. Snyder
  • Patent number: 5264459
    Abstract: The present invention discloses improved methods for the treatment of autoimmune diseases using .beta.-adrenergic agonists, and particularly, .beta..sub.2 -adrenergic agonists. The treatment of animals with either EAE or EAN using the .beta..sub.2 -adrenergic agonist terbutaline significantly suppressed clinical disease. A Phase I safety treatment trial with terbutaline was conducted in MS patients. Twenty-four patients were treated for 4 weeks. No obvious side effects were observed. At 4 weeks, 15 of the 24 patients improved on neurologic rating scale and 17 patients reported subjective improvement. Treatment of rats with EAMG, an animal model of tThe government may own rights in the present invention pursuant to NIH grants 2 RO1 NS18413-07A1 and PO1NS-24575-03.
    Type: Grant
    Filed: July 13, 1992
    Date of Patent: November 23, 1993
    Assignee: ARCH Development Corporation
    Inventors: Ewa E. Chelmicka-Schorr, Barry G. W. Arnason, Anthony T. Reder, Louis Cohen
  • Patent number: 5262424
    Abstract: A compound of the structure ##STR1## wherein R.sup.1 and R.sup.2 are each, independently, hydrogen or --CONHSO.sub.2 --Ar; andAr is phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, quinoxalyl, thienyl, thionaphthyl, furyl, benzofuryl, benzodioxyl, benzoxazolyl, benzoisoxazolyl, or benzodioxolyl; wherein the Ar group may be optionally mono-, di-, or tri-substituted; with the proviso that R.sup.1 and R.sup.2 are not both hydrogen;or a pharmaceutically acceptable salt thereof which by virtue of its immunosuppressive activity is useful in treating transplantation rejection, host vs. graft disease, autoimmune diseases and diseases of inflammation; by virtue of its antitumor activity is useful in treating solid tumors; and by virtue of its antifungal activity is useful in treating fungal infections.
    Type: Grant
    Filed: November 17, 1992
    Date of Patent: November 16, 1993
    Assignee: American Home Products Corporation
    Inventor: Wenling Kao
  • Patent number: 5262174
    Abstract: The treatment of viral infections with a lithium salt and one of cytarabine or idoxuridine.
    Type: Grant
    Filed: July 18, 1991
    Date of Patent: November 16, 1993
    Assignee: Efamol Limited
    Inventor: David F. Horrobin
  • Patent number: 5260337
    Abstract: This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and the treatment of muscle spasms and associated pain, soreness and tightness of muscles in mammalian organism, said composition comprising:(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and(ii) an amount effective in the treatment of muscle spasms of at least one of the muscle relaxants, or a therapeutically active stereoisomer thereof, substantially free of its other stereoisomers.
    Type: Grant
    Filed: July 29, 1992
    Date of Patent: November 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Robert T. Sims, Thomas N. Gates, William Slivka
  • Patent number: 5260289
    Abstract: A composition for treating pain, which contains dibucaine, a pharmaceutically acceptable salt of salicylic acid, calcium bromide, and antiphlogistic steroid(s) as active ingredients; and a method for reducing pain, which comprises injecting said composition into the location of pain. Further, the present invention provides a composition containing antiphlogistic steroid as an active ingredient, which is for reinforcing pain relief action of a composition containing dibucaine, a pharmaceutically acceptable salt of salicylic acid, and calcium bromide; and a novel use of antiphlogistic steroid in the treatment of pain.
    Type: Grant
    Filed: June 12, 1992
    Date of Patent: November 9, 1993
    Assignee: Vitacain Pharmaceutical Co., Ltd.
    Inventors: Masayoshi Hyodo, Masataka Akiyoshi
  • Patent number: 5260331
    Abstract: The invention concerns compounds having formula: ##STR1## or a salt thereof, wherein E represents hydrogen, lower alkyl or a group Ar.sup.1 --A.sup.1 --; Ar and Ar.sup.1 are the same or different aryl groups (including heteroaryl) which are optionally substituted, e.g. by one or more substituents commonly used in pharmaceutical chemistry; A and A.sup.1 are the same or different alkylene groups having one or two carbon atoms linking Ar or Ar.sup.1 to N and optionally substituted by lower alkyl and/or optionally substituted aryl, B is an alkylene group of 3 or 4 carbon atoms, which may be substituted by lower alkyl; D.sup.1 represents halogen, CH.sub.3, CR.sup.1 R.sup.2 NH.sub.2, SO.sub.3 H or SO.sub.2 NR.sup.6 R.sup.7 where R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl and R.sup.6 and R.sup.7 are each hydrogen, lower alkyl or aralkyl of 7 to 12 carbon atoms or R.sup.6 and R.sup.
    Type: Grant
    Filed: November 2, 1992
    Date of Patent: November 9, 1993
    Assignee: John Wyeth & Brother Limited
    Inventors: John F. White, Michael C. W. Minchin, Christine Ennis
  • Patent number: 5260340
    Abstract: A method for preventing acetaminophen toxicity in a mammal is provided. An acetaminophen toxicity inhibiting amount of beta-carotene is administered before, simultaneously with, after, or any combination thereof, administering acetaminophen to the mammal. Methods for reducing acetaminophen toxicity in a mammal in need of such treatment and for increasing the maximum amount of acetaminophen that can be administered to a mammal without the mammal exhibiting acetaminophen toxicity are also provided. Acetaminophen toxicity reducing amounts and acetaminophen toxicity preventing amounts, respectively, are administered. In another embodiment, a non-steroidal analgesic and anti-inflammatory composition of acetaminophen and an acetaminophen toxicity preventing amount of beta-carotene is provided.
    Type: Grant
    Filed: November 19, 1992
    Date of Patent: November 9, 1993
    Inventors: Steven Baranowitz, Paul F. Maderson
  • Patent number: 5260339
    Abstract: Novel 4-phenyl-1,3-benzodiazepines and 2-amino-.alpha.-phenylphenethylamines, novel intermediates thereof, and methods of preparing same are described. These benzodiazepines are useful as antidepressants, analgetics and anticonvulsants. The 2-amino-.alpha.-phenylphenethylamines are useful as anticonvulsant and neuroprotective agents.
    Type: Grant
    Filed: October 8, 1992
    Date of Patent: November 9, 1993
    Assignee: Hoechst-Roussel Pharmaceuticals Incorporated
    Inventors: Lawrence L. Martin, Manfred Worm, Charles A. Crichlow
  • Patent number: 5260324
    Abstract: A composition is described for use in memory and learning enhancement or for treatment of a cognitive disorder or a psychotic disorder. This composition contains the compound D-cycloserine and D-alanine and provides reduced adverse side effects typically associated with chronic D-cycloserine use.
    Type: Grant
    Filed: November 6, 1992
    Date of Patent: November 9, 1993
    Assignee: G. D. Searle & Company
    Inventors: Alex A. Cordi, Michel R. Jans
  • Patent number: 5256691
    Abstract: A stable oil-in-water type emulsified composition, which comprises a stable non-steroidal antiphlogistic and analgesic drug by using a combination of a monoalkylglyceryl ether, particularly an ether compound having a C.sub.12-22 alkyl group in the alkyl moiety and a hydrophilic surface-active agent.In particular, when the drug is in the form of salts, the stability of the composition can be increased thereof by adding an ion consisting of HSO.sub.3 -, SO.sub.3 -- or S.sub.2 O.sub.5 --.
    Type: Grant
    Filed: October 22, 1991
    Date of Patent: October 26, 1993
    Assignee: Shiseido Company Ltd.
    Inventor: Takashi Suzuki